Cargando…
A Systematic Review and Meta-analysis of Optimized CMV Preemptive Therapy and Antiviral Prophylaxis for CMV Disease Prevention in CMV High-Risk (D+R-) Kidney Transplant Recipients
The optimal strategy for cytomegalovirus (CMV) disease prevention in CMV donor/recipient kidney transplant recipients remains uncertain. Conclusions of prior meta-analyses that CMV disease rates with preemptive therapy (PET) and universal prophylaxis (UP) were comparable may have been affected by in...
Autores principales: | Kumar, Lakshin, Murray-Krezan, Cristina, Singh, Nina, Brennan, Daniel C., Rakita, Robert M., Dasgupta, Sayan, Fisher, Cynthia E., Limaye, Ajit P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348730/ https://www.ncbi.nlm.nih.gov/pubmed/37456587 http://dx.doi.org/10.1097/TXD.0000000000001514 |
Ejemplares similares
-
Donor CMV Reactivation as a Novel Risk Factor for CMV Replication in Seropositive Liver Transplant Recipients
por: Limaye, Ajit P., et al.
Publicado: (2020) -
Stimulatory Effect of CMV Immunoglobulin on Innate Immunity and on the Immunogenicity of CMV Antigens
por: Deml, Ludwig, et al.
Publicado: (2021) -
Impact of CMV PCR Blips in Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation
por: Lodding, Isabelle P., et al.
Publicado: (2018) -
1569. Incidence, Risk Factors, and Impact of Antiviral Prophylaxis Duration on Cytomegalovirus (CMV) Disease in High-Risk Donor Seropositive/Recipient Seronegative [D+R−] Orthotopic Heart Transplant Recipients (OHTR)
por: Carcoana, Allison Dumitriu, et al.
Publicado: (2018) -
Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients
por: Kim, Jong Man, et al.
Publicado: (2015)